There is a need for novel effective and safe
therapies for metastatic
breast cancer based on targeting
tumor-specific molecular markers of
cancer. Human aspartyl (asparaginyl) β-
hydroxylase (HAAH) is a highly conserved
enzyme that hydroxylates
epidermal growth factor-like domains in transformation-associated
proteins and is overexpressed in a variety of
cancers, including
breast cancer. A fully human
monoclonal antibody (mAb) PAN-622 has been developed to HAAH. In this study, they describe the development of PAN-622 mAb as an agent for imaging and
radioimmunotherapy of metastatic
breast cancer. PAN-622 was conjugated to several
ligands such as
DOTA, CHXA″, and
DTPA to enable subsequent radiolabeling and its immunoreactivity was evaluated by an HAAH-specific
enzyme-linked
immunosorbent assay and binding to the HAAH-positive cells. As a result, DTPA-PAN-622 was chosen to investigate biodistribution in healthy CD-1 female mice and 4T1 mammary
tumor-bearing BALB/c mice. The 111In-DTPA-pan622 mAb concentrated in the primary
tumors and to some degree in lung
metastases as shown by SPECT/CT and Cherenkov imaging. A pilot
therapy study with 213Bi-DTPA-PAN-622 demonstrated a significant effect on the primary
tumor. The authors concluded that human mAb PAN-622 to HAAH is a promising
reagent for development of imaging and possible therapeutic agents for the treatment of metastatic
breast cancer.